Overview

Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2019-12-09

Target enrollment:

Participant gender:

Summary

This prospective, non randomized multicenter phase II study, will determine the feasibility of individualized dose of irinotecan with the UGT1A1 polymorphism, in patients with metastatic colorectal cancer treated with FOLFIRI.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Jean Perrin

Treatments:

Camptothecin
Irinotecan